Background: Serum protein electrophoresis (SPE), immunofixation, and free light chain assays are recommended for monoclonal gammopathy (MG) screening. High serum globulins might be an inexpensive and useful parameter to decide on a workup for MG. Objective: The objective of the study was to determine a serum globulin cutoff that predicts an abnormal SPE. Materials and methods: A retrospective, observational study performed in a hematological referral center. SPE, serum albumin, and globulins from patients with MG suspicion between January 2013 and August 2019 were collected. ROC curves for serum globulin and albumin/globulin ratio (A/G) were performed to identify their diagnostic yield for identifying the presence of M protein. Results: A total of 1578 SPE were collected; 1010 (64%) exhibited an M protein. After performing a ROC curve analysis, the best serum globulin value was ≥ 2.6 g/dL, with a sensitivity and specificity of 52% and 79.9%, respectively. Accordingly, the best A/G ratio cutoff (≤ 1.69) yielded a sensitivity of 58.9% and specificity of 79%. After a ROC curve sub-analysis on patients with an M protein ≥ 1 g/dL, the best serum globulin cutoff was ≥ 2.8 g/dL, with a sensitivity and specificity of 87.3% and 84.1%, respectively. The best A/G ratio cutoff was ≤ 1.38, with a sensitivity of 84.1% and specificity of 88.6%. Conclusions: A serum globulin and/or A/G cutoff can be used to guide the clinical decision-making for early detection of MG and could decrease its underdiagnosis. This inexpensive laboratory testing strategy could be used to screen adult populations above the age of 50 in a cost-efficient way.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.